Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous

AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other di...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 12; no. 10; pp. 1621 - 1625
Main Authors Sawada, Koji, Takahashi, Ryouki, Saniabadi, Abbi R, Ohdo, Maiko, Shimoyama, Takashi
Format Journal Article
LanguageEnglish
Published United States Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan 14.03.2006
Baishideng Publishing Group Co., Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. RESULTS: CF in active UC was strikingly high compared with all other groups (x^2〈0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (x^2〈0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
AbstractList AIMTo investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODSCF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA.RESULTSCF in active UC was strikingly high compared with all other groups (c2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (c2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation.CONCLUSIONElevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. RESULTS: CF in active UC was strikingly high compared with all other groups (χ 2 <0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (χ 2 <0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. CF in active UC was strikingly high compared with all other groups (c2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (c2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA. RESULTS: CF in active UC was strikingly high compared with all other groups (x^2〈0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (x^2〈0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate, suggesting that elevated CF was not a consequence of acute inflammation. CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance) and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
R5; AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODS: CF was assayed in 284 subjects: 61 with active and 63 with inactive ulcerative colitis (UC), 45 who had proctocolectomy, 35 with active and 20 with inactive Crohn's disease (CD), 40 with other diseases and 20 healthy controls. Trypsin inhibitor (TI) and TI antibody (TI-Ab) were measured in plasma and CF complex by ELISA.RESULTS: CF in active UC was strikingly high compared with all other groups (χ2<0.001). Similarly, CF was significantly higher in active CD than in inactive CD or in controls (χ2<0.01). In UC, high CF and TI-Ab were associated with the need for operations. Further, high CF, CF/fibrinogen ratio, low TI and high TI-Ab in plasma were associated with disease activity or refractoriness to medication. Elevated CF was not associated with acute reactants like C-reactive protein and white blood cell counts except for erythrocyte sedimentation rate,suggesting that elevated CF was not a consequence of acute inflammation.CONCLUSION: Elevated CF in active IBD appears to be morbigenous. CF promotes IBD via two main mechanisms, quenching of TI (an anti-inflammatory substance)and impairing microvascular perfusion by forming protein aggregates. CF may also serve as a biomarker of chronic IBD. Additional studies are warranted to fully evaluate the role of CF in IBD and the outcome should contribute to a better understanding of the pathogenesis of IBD.
Author Koji Sawada Ryouki Takahashi Abbi R Saniabadi Maiko Ohdo Takashi Shimoyama
AuthorAffiliation Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan Japan Immunoresearch Laboratories.Takasaki, Japan
AuthorAffiliation_xml – name: Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan
Author_xml – sequence: 1
  givenname: Koji
  surname: Sawada
  fullname: Sawada, Koji
  email: f-sawada@leaf.ocn.ne.jp
  organization: Department of Gastroenterology, Fujimoto Hospital Medicine, 3-15-27 Konda Habikino, Osaka 583-0857, Japan. f-sawada@leaf.ocn.ne.jp
– sequence: 2
  givenname: Ryouki
  surname: Takahashi
  fullname: Takahashi, Ryouki
– sequence: 3
  givenname: Abbi R
  surname: Saniabadi
  fullname: Saniabadi, Abbi R
– sequence: 4
  givenname: Maiko
  surname: Ohdo
  fullname: Ohdo, Maiko
– sequence: 5
  givenname: Takashi
  surname: Shimoyama
  fullname: Shimoyama, Takashi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16570358$$D View this record in MEDLINE/PubMed
BookMark eNpVUU1rGzEUFCWhcdLeeypLKb2to8_V6lIIIf2AQC7pWX2rldZydyVHWtv431fGph8nwXszo5k31-gixGARekfwkkne3u7Xw3JH6NKXAWkoeYUWlBJV05bjC7QgGMtaMSqv0HXOa4wpY4K-RlekERIz0S7Qz4fR7mC2fbUZIU9QmXSIznfJhzjYUPlQbWD2Nsy52vt5VYGZ_c6WuRthmmCO6VB1cW_HqvfZQi6rXE0xdb7Q4za_QZcOxmzfnt8b9OPLw_P9t_rx6ev3-7vH2nCB59o5EKLjTlBlWqp6Z3pCrKOsYdhw1vOucVJCI2yJ2QqQinSuA9oyylsFwG7Q55PuZttNtjfFcYJRb5KfIB10BK__3wS_0kPcaU4op6otAh9PAnsIDsKg13GbQrGsy5Upxk25JsUF9un8T4ovW5tnPfls7DhCsCWubmRLcCNJAeIT0KSYc7LujxeC9bG9o64u7enSnj62Vyjv_83wl3CuqwA-nDVXMQwvvrjswPxyfrSaEqEwbxT7DXtvpsQ
CitedBy_id crossref_primary_10_1016_j_bbagen_2006_09_026
crossref_primary_10_1016_j_amjmed_2009_03_040
crossref_primary_10_1515_cclm_2022_0423
crossref_primary_10_1016_j_amjmed_2008_03_011
crossref_primary_10_1016_j_amjmed_2015_03_009
crossref_primary_10_1016_j_revmed_2009_12_019
crossref_primary_10_2174_1573397118666220325110737
crossref_primary_10_1097_RHU_0b013e318289e06e
crossref_primary_10_1016_j_revmed_2014_09_007
Cites_doi 10.1016/0016-5085(79)90384-6
10.1515/CCLM.2005.001
10.1001/archinte.1964.00280110128024
10.1016/S0025-6196(12)65200-8
10.1016/0016-5085(87)90125-9
10.1016/S0140-6736(89)91078-7
10.1046/j.1365-2249.2000.01210.x
10.1016/0190-9622(91)70048-7
10.1182/blood.V10.9.945.945
10.1159/000208756
10.1016/0016-5085(92)91112-H
10.1016/S0140-6736(86)90111-X
10.1046/j.1365-2141.1996.4791016.x
10.1111/j.1365-2796.1993.tb00752.x
10.1111/j.1442-200x.2005.02039.x
10.1056/NEJM199406303302601
10.1056/NEJM196804112781503
10.1111/j.1365-2559.1992.tb00360.x
10.1159/000418554
10.7326/0003-4819-85-4-464
10.1152/ajpheart.00885.2004
10.1002/jca.2920070209
10.1093/ajcp/58.5.524
10.1093/rheumatology/35.1.102
10.1111/j.1365-2141.1994.tb05003.x
ClassificationCodes R5
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
– notice: 2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006
DBID 2RA
92L
CQIGP
W91
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
2B.
4A8
92I
93N
PSX
TCJ
5PM
DOI 10.3748/wjg.v12.i10.1621
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous
EISSN 2219-2840
EndPage 1625
ExternalDocumentID wjg200610020
10_3748_wjg_v12_i10_1621
16570358
21590469
Genre Journal Article
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CDYEO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
4A8
PSX
5PM
ID FETCH-LOGICAL-c450t-ffa55b4f529c829dfcd11ef23630c43d4b6f77a65e62185a791bfba2832489aa3
IEDL.DBID RPM
ISSN 1007-9327
IngestDate Fri Sep 01 02:36:13 EDT 2023
Tue Feb 13 23:29:29 EST 2024
Fri Oct 25 21:54:29 EDT 2024
Fri Aug 23 00:28:07 EDT 2024
Wed Oct 16 00:47:24 EDT 2024
Thu Nov 24 20:29:55 EST 2022
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 10
Keywords Inflammatory bowel disease
Acute colitis
Cryofibrinogen
Trypsin inhibitor
Trypsin inhibitor antibody
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c450t-ffa55b4f529c829dfcd11ef23630c43d4b6f77a65e62185a791bfba2832489aa3
Notes Inflammatory bowel disease
Inflammatory bowel disease; Cryofibrinogen;Trypsin inhibitor; Trypsin inhibitor antibody; Acute colitis
Trypsin inhibitor
14-1219/R
Trypsin inhibitor antibody
Acute colitis
R441
Cryofibrinogen
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Telephone: +81-729-585566 Fax: +81-729-585564
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Koji Sawada. MD, PhD, Department of Gastroenterology, Fujimoto Hospital Medicine, 3-15-27 Konda Habikino, Osaka 583-0857, Japan. f-sawada@leaf.ocn.ne.jp
OpenAccessLink https://doi.org/10.3748/wjg.v12.i10.1621
PMID 16570358
PQID 67810671
PQPubID 23479
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4124298
wanfang_journals_wjg200610020
proquest_miscellaneous_67810671
crossref_primary_10_3748_wjg_v12_i10_1621
pubmed_primary_16570358
chongqing_backfile_21590469
PublicationCentury 2000
PublicationDate 2006-03-14
PublicationDateYYYYMMDD 2006-03-14
PublicationDate_xml – month: 03
  year: 2006
  text: 2006-03-14
  day: 14
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationTitle_FL WORLD JOURNAL OF GASTROENTEROLOGY
PublicationYear 2006
Publisher Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan
Baishideng Publishing Group Co., Limited
Publisher_xml – name: Department of Gastroenterology,Fujimoto, Hospital Medicine, Osaka and Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya,Japan%Wakamoto Pharmaceuticals, Sagami Laboratory, Kanagawa, Japan%Japan Immunoresearch Laboratories.Takasaki, Japan%Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan
– name: Baishideng Publishing Group Co., Limited
References ref13
ref12
ref15
ref14
ref30
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref19
  doi: 10.1016/0016-5085(79)90384-6
– ident: ref15
  doi: 10.1515/CCLM.2005.001
– ident: ref22
– ident: ref4
  doi: 10.1001/archinte.1964.00280110128024
– ident: ref12
  doi: 10.1016/S0025-6196(12)65200-8
– ident: ref13
  doi: 10.1016/0016-5085(87)90125-9
– ident: ref10
  doi: 10.1016/S0140-6736(89)91078-7
– ident: ref23
  doi: 10.1046/j.1365-2249.2000.01210.x
– ident: ref5
  doi: 10.1016/0190-9622(91)70048-7
– ident: ref30
– ident: ref1
  doi: 10.1182/blood.V10.9.945.945
– ident: ref3
  doi: 10.1159/000208756
– ident: ref27
  doi: 10.1016/0016-5085(92)91112-H
– ident: ref9
  doi: 10.1016/S0140-6736(86)90111-X
– ident: ref2
  doi: 10.1046/j.1365-2141.1996.4791016.x
– ident: ref6
  doi: 10.1111/j.1365-2796.1993.tb00752.x
– ident: ref21
– ident: ref24
  doi: 10.1111/j.1442-200x.2005.02039.x
– ident: ref17
  doi: 10.1056/NEJM199406303302601
– ident: ref20
  doi: 10.1056/NEJM196804112781503
– ident: ref11
  doi: 10.1111/j.1365-2559.1992.tb00360.x
– ident: ref28
  doi: 10.1159/000418554
– ident: ref26
  doi: 10.7326/0003-4819-85-4-464
– ident: ref16
  doi: 10.1152/ajpheart.00885.2004
– ident: ref18
– ident: ref29
  doi: 10.1002/jca.2920070209
– ident: ref25
  doi: 10.1093/ajcp/58.5.524
– ident: ref8
  doi: 10.1093/rheumatology/35.1.102
– ident: ref7
  doi: 10.1111/j.1365-2141.1994.tb05003.x
– ident: ref14
SSID ssj0023352
Score 1.8849211
Snippet AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63...
To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). CF was assayed in 284 subjects: 61 with active and 63 with inactive...
AIMTo investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODSCF was assayed in 284 subjects: 61 with active and 63 with...
R5; AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD).METHODS: CF was assayed in 284 subjects: 61 with active and...
AIM: To investigate the role of cryofibrinogen (CF) in active inflammatory bowel disease (IBD). METHODS: CF was assayed in 284 subjects: 61 with active and 63...
SourceID pubmedcentral
wanfang
proquest
crossref
pubmed
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1621
SubjectTerms Adolescent
Adult
Antibodies - blood
Biomarkers - blood
Blood Sedimentation
C-Reactive Protein - metabolism
Chronic Disease
Cryoglobulins - metabolism
Female
Fibrinogen - metabolism
Fibrinogens, Abnormal - metabolism
Humans
Inflammatory Bowel Diseases - blood
Inflammatory Bowel Diseases - physiopathology
Male
Middle Aged
Rapid Communication
Trypsin Inhibitors - blood
冷纤维蛋白原
疾病炎症
等离子体
药物抗体
Title Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous
URI http://lib.cqvip.com/qk/84123X/200610/21590469.html
https://www.ncbi.nlm.nih.gov/pubmed/16570358
https://search.proquest.com/docview/67810671
https://d.wanfangdata.com.cn/periodical/wjg200610020
https://pubmed.ncbi.nlm.nih.gov/PMC4124298
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSgguCMQrlFIfuHDIbmI7Dx9R1aqq1KoHKvUWbMdeAhvvdnfpin_PjOMUVr1xTSzLmZl4vvGMvyHkU80kU0oin3buUuGcSGvFJF7wUTxTmWGhmvDyqjy_ERe3xe0eKca7MKFo3-hu4uf9xHffQ23lsjfTsU5sen15gh2Tmayn-2QfDHQM0WOUhZeIQoozq1IAJ9WQm0SWlen2x2xyn7NJh1tFyUKXGCz94Njw_SlsN352Bw5j10U9wp2PyyefbJV3ys_-8UxnL8jzCCnpl2HpL8me9a_It9O5vQcc2dIl4ONeUbP6DXakV51fgM3QztNIqbqmeBZLVdj44LkDG-lD7p3qxdbOaczh0G5N-8VKR1rX1-Tm7PTryXkauymkRhTZJnVOFYUWrmDSgIZaZ9o8t47xkmdG8Fbo0lWVKgsLkqkLVclcO62wlZGopVL8DTnwC2_fEcolL43NLdcmxwkBdBqlRAvYkhumRUIOH4QJ3tj8RI6pBsCFxGg8IZ9H8TbLgVKjgVAENdSAhiBsZ02HsQmsIyHHo_wbsHtMZihv4SMbcLLIfgcj3g7a-DtXVGlCqh09PQxARu3dN2BogVk7GlZCjqJGm_hHr3FlePqCjLXZ-_-e-ZA8G85weJqLD-Rgs_pljwDVbPTHYMV_ACa0-E0
link.rule.ids 230,315,730,783,787,888,27938,27939,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwENaUMkx74TG8TCnVgQsHO7Ykv45Mp50ATYdDy_QmJEUKprGSJmkz8OvZ9aMQeoJr7NFY-Vbab7Wrbwl5W7CSKVWinnbiQuGcCAvFSrzgo3isYsOaasLRaTY8Fx8v0ostkvZ3YZqifaOryE_ryFffmtrKeW0GfZ3Y4PPoEDsms7IY3CP3Yb3GWR-kd3EWXiNqkpxxHgI9ydvsJOqsDNbfJ9FNwqIKN4uMNX1isPiDY8v3Hdhw_OQKXMamk7rDPO8WUD5YK--Un_zhm44fkS_9rNqSlMvoeqUj8_Mvwcd_nvZj8rBjq_R9-_gJ2bL-Kfl6NLU3QFHHdA7Uu1bULH6AiepF5WdgjrTytFNrXVI85qWq2VPhdwfmVzdpfapnazulXXqIVktazxa6U4x9Rs6Pj84Oh2HXqCE0Io1XoXMqTbVwKSsNgD92Zpwk1jGe8dgIPhY6c3mustTCX16kKi8T7bTCLkmiKJXiz8m2n3n7klBe8szYxHJtEhwQ-KxRSoyBtnLDtAjI3i1K4OjNJcpXSeAtJQb6AXnX4ybnrVqHhCgHoZcAvQToZYVhD3xHQA56YCUsKcyTKG9hkhL8NwrrwRsvWph_j9XZSkDyDQO4fQHFujefAJiNaHcHXkD2O1OR3WaxxC_Dgx0Uw41f_ffIB2RneDY6kScfTj_tkd32qIiHiXhNtleLa7sP5Gml3zRL5RdbXRpS
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwENZAGR4XHsPLlFIduHCwY0vy68iUZsqjnR7oTIeLkGQpmMZKSNJm4Nez60dp6K3XWKOx8q2032rX3xLytmAlU6pEPe3EhcI5ERaKlfiBj-Kxig1rqwkPj7KDE_HpND290uqrLdo3uo78tIl8_aOtrZw3ZjTUiY2OD_ewYzIri9G8cqPb5A7s2bgYAvU-1sJPidpEZ5yHQFHyLkOJWiuj9c9JdJGwqMYDI2NtrxgsAOHY9v0-HDp-8gvcxqajusY-rxdR3l0r75SfXPFP40fk27CyrizlLDpf6cj8-U_08UZLf0we9qyVvu-GPCG3rH9Kvu9P7QVQ1YrOgYI3iprFbzBVvaj9DMyS1p72qq1Lite9VLVnK_zuwAybNr1P9Wxtp7RPE9F6SZvZQvfKsc_IyXj_695B2DdsCI1I41XonEpTLVzKSgNGUDlTJYl1jGc8NoJXQmcuz1WWWvjbi1TlZaKdVtgtSRSlUvw52fIzb18SykueGZtYrk2CEwKvNUqJCugrN0yLgGxfIgUO35yhjJUE_lJiwB-QdwN2ct6pdkiIdhB-CfBLgF_WGP7AewRkdwBXwtbCfInyFhYpwY-jwB6MeNFB_W-u3l4Ckm8YweUAFO3efAKAtuLdPYAB2enNRfaHxhLfDC94UBQ3fnXjmXfJveMPY_nl49HnbfKguzHiYSJek63V4tzuAIda6TftbvkLHuYc0g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevated+plasma+cryofibrinogen+in+patients+with+active+inflammatory+bowel+disease+is+morbigenous&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Sawada%2C+Koji&rft.au=Takahashi%2C+Ryouki&rft.au=Saniabadi%2C+Abbi+R&rft.au=Ohdo%2C+Maiko&rft.date=2006-03-14&rft.issn=1007-9327&rft.volume=12&rft.issue=10&rft.spage=1621&rft.epage=1625&rft_id=info:doi/10.3748%2Fwjg.v12.i10.1621&rft.externalDBID=NO_FULL_TEXT
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fwjg%2Fwjg.jpg